Drug–drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS

References

• U.S. Food and Drug Administration. Coronavirus (COVID-19) | drugs: FDA authorizes first oral antiviral for treatment of COVID-19. Accessed 10 Feb 2023. https://www.fda.gov/drugs/emergency-preparedness-drugs/emergency-use-authorizations-drugs-and-non-vaccine-biological-products.
   Google Scholar
• Lamb YN. Nirmatrelvir plus ritonavir: first approval. Drugs. 2022 Apr;82(5):585–591. doi: 10.1007/s40265-022-01692-5
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022 Apr 14;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023 Feb 8;76(3):e342–e349. doi: 10.1093/cid/ciac443
   PubMed Web of Science ®Google Scholar
• Marzolini C, Kuritzkes DR, Marra F, et al. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (paxlovid) and comedications. Clin Pharmacol Ther. 2022 Dec;112(6):1191–1200.
   PubMed Web of Science ®Google Scholar
• Salerno DM, Jennings DL, Lange NW, et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. Am J Transplant. 2022 Aug;22(8):2083–2088.
   PubMed Web of Science ®Google Scholar
• Yu M, Liu M, Zhang W, et al. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19(6):513–522. doi: 10.2174/1389200219666180129151948
   PubMed Web of Science ®Google Scholar
• Reis S, Metzendorf MI, Kuehn R, et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst Rev. 2022 Sep 20;9(9): CD015395. 10.1002/14651858.CD015395.pub2
   PubMedGoogle Scholar
• Lemaitre F, Budde K, Van Gelder T, et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19. Ther Drug Monit. 2022 Aug 9;45(2): 191–199. 10.1097/FTD.0000000000001014
   PubMed Web of Science ®Google Scholar
• Mecadon K, Arvanitis P, Farmakiotis D, et al. Single-center experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression. Clin Transplant. 2022 Aug;36(8):e14752.
   PubMed Web of Science ®Google Scholar
• Cordero C G, de Vicente M S-T. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series. Eur J Hosp Pharm. 2022;ejhpharm-2022–003544. doi: 10.1136/ejhpharm-2022-003544
   Google Scholar
• Dewey KW, Yen B, Lazo J, et al. Nirmatrelvir/Ritonavir Use with Tacrolimus in Lung Transplant Recipients: A Single-center Case Series. Transplantation. 2022 Oct 28;107(5):1200–1205. 10.1097/TP.0000000000004394
   PubMed Web of Science ®Google Scholar
• Lange NW, Salerno DM, Jennings DL, et al. Nirmatrelvir/Ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. Am J Transplant. 2022 Jul;22(7):1925–1926.
   PubMed Web of Science ®Google Scholar
• Prikis M, Cameron A. Paxlovid (nirmatelvir/ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: A case report. Transplant Proc. 2022 Jul;54(6):1557–1560. doi: 10.1016/j.transproceed.2022.04.015
   PubMed Web of Science ®Google Scholar
• Berar Yanay N, Bogner I, Saker K, et al. Paxlovid-tacrolimus drug-drug interaction in a 23-year-old female kidney transplant patient with COVID-19. Clin Drug Investig. 2022 Aug;42(8):693–695.
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Sommet A, Lacroix I, et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine. 2006 Dec;73(6):629–632.
   PubMed Web of Science ®Google Scholar
• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 Oct 7;356(9237):1255–1259. doi: 10.1016/S0140-6736(00)02799-9
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002 Jan;11(1):3–10. doi: 10.1002/pds.668
   PubMed Web of Science ®Google Scholar
• Li Q-SZ M, Zhang Q-S, Liu X-L. Adverse events associated with nirmatrelvir/ritonavir: a pharmacovigilance analysis based on FAERS. Pharmaceuticals. 2022 Nov 24;15(12):1455. doi: 10.3390/ph15121455
   Web of Science ®Google Scholar
• Hult S, Sartori D, Bergvall T, et al. A feasibility study of drug-drug interaction signal detection in regular pharmacovigilance. Drug Saf. 2020 Aug;43(8):775–785.
   PubMed Web of Science ®Google Scholar
• Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015 May;15(5):1313–1322. doi: 10.1111/ajt.13111
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009 Feb;4(2):481–508. doi: 10.2215/CJN.04800908
   PubMed Web of Science ®Google Scholar
• Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020 Feb;44(2):140–152. doi: 10.1111/aor.13551
   PubMed Web of Science ®Google Scholar
• Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol. 2013;37(6):602–612. doi: 10.1159/000351648
   PubMed Web of Science ®Google Scholar
• Wang AX, Koff A, Hao D, et al. Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients. Am J Transplant. 2022 Aug;22(8):2117–2119.
   PubMed Web of Science ®Google Scholar
• Sindelar M, McCabe D, Carroll E. Tacrolimus drug-drug interaction with nirmatrelvir/ritonavir (paxlovid) managed with phenytoin. J Med Toxicol. 2023 Jan;19(1):45–48. doi: 10.1007/s13181-022-00922-2
   PubMed Web of Science ®Google Scholar
• Kwon EJ, Yun GA, Park S, et al. Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient. Kidney Res Clin Pract. 2022 Nov;41(6):768–770.
   PubMed Web of Science ®Google Scholar
• Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021 Mar;93(3):1449–1458.
   PubMed Web of Science ®Google Scholar
• Copur S, Berkkan M, Basile C, et al. Post-acute COVID-19 syndrome and kidney diseases: what do we know? J Nephrol. 2022 Apr;35(3):795–805.
   PubMed Web of Science ®Google Scholar
• Bruchfeld A. The COVID-19 pandemic: consequences for nephrology. Nat Rev Nephrol. 2021 Feb;17(2):81–82. doi: 10.1038/s41581-020-00381-4
   PubMed Web of Science ®Google Scholar
• Amann K, Boor P, Wiech T, et al. COVID-19 effects on the kidney. Pathologe. 2021 Nov;42(Suppl 1):76–80.
   PubMed Web of Science ®Google Scholar
• Singh A, Kamath A. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data. Expert Opin Drug Saf. 2021 Dec;20(12):1559–1564. doi: 10.1080/14740338.2021.1962846
   PubMed Web of Science ®Google Scholar
• Gerard AO, Laurain A, Fresse A, et al. Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database. Clin Pharmacol Ther. 2021 Apr;109(4):1021–1024.
   PubMed Web of Science ®Google Scholar